Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03275753 · ClinicalTrials.gov registry record
Visual Function Tests in Age-related Macular Degeneration
A clinical trial, sponsored by ORA.
- Terminated
- Registry status
- 200
- Enrollment target
NCT03275753: Clinical Trial study, sponsored by ORA.
NCT03275753 is a clinical trial that was terminated before completion, run by ORA. The registered enrollment target is 200 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03275753 was terminated before completion, sponsored by ORA.
- TERMINATED
- Registry status
- 200 participants
- Enrollment target
Study Summary
The goal of this study is to assess a battery of visual function tests in subjects with non-exudative age-related macular degeneration
Primary Outcome
Critical flicker fusion will be tested using a computer based test for different stimulus colors, white, red, green and blue. A wide range of luminance and contrast levels will be tested. The subject would be seated in front of the monitor. The non-study eye will be occluded. Subjects would be given adequate practice tests prior to performing the actual test. The stimulus will be presented on the monitor screen and the subject indicates perceiving the stimulus by pressing a test button.
Interventions
- OTHER Visual Function Tests
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2022-12-31 |
Why NCT03275753 stopped before completion
NCT03275753 is an observational study that tracks outcomes without assigning an intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Visual Function Tests is the first listed.
NCT03275753 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03275753 about?
NCT03275753 is a clinical study titled "Visual Function Tests in Age-related Macular Degeneration". The goal of this study is to assess a battery of visual function tests in subjects with non-exudative age-related macular degeneration
What is the current status of trial NCT03275753?
This trial is currently terminated. The enrollment target is 200 participants. The study started on 2017-09-21. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03275753?
The interventions under investigation include: Visual Function Tests (OTHER).
Who is sponsoring clinical trial NCT03275753?
This trial is sponsored by ORA, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI